Washington, D.C. 20549

                            FORM 8K

                        Current Report
               Pursuant to Section 13 or 15(d) of
              The Securities Exchange Act of 1934

  Date of Report (Date of earliest event reported): April
19, 2005

                        JOHNSON & JOHNSON

     (Exact name of registrant as specified in its charter)

    New Jersey                1-3215              22-1024240

(State or other             Commission       (I.R.S. Employer
jurisdiction                File Number)    Identification No.)
of incorporation)

 One Johnson & Johnson Plaza, New Brunswick, New Jersey

   (Address of principal executive offices)    (zip code)

Registrant's telephone number including area code:
(732) 524-0400

Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-
2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-
4(c) under the Exchange Act (17 CFR 240.13e-4(c)
Item 8.01 Other Events

New Brunswick, NJ (April 19, 2005) - Johnson & Johnson
(NYSE: JNJ) announced a definitive agreement under
which Ortho-McNeil Pharmaceutical, Inc., a subsidiary of
Johnson & Johnson, would acquire Peninsula Pharmaceuticals,
Inc., a privately held biopharmaceutical company focused on
developing and commercializing antibiotics to treat life-
threatening infections.

Peninsula's lead product candidate, doripenem, is a broad-
spectrum antibiotic and a new member of the carbapenem class
of beta-lactam antibiotics. Peninsula is currently
evaluating doripenem in six Phase III clinical trials. In
addition, doripenem received Fast Track designation from the
U.S. Food and Drug Administration (FDA) for the treatment of
nosocomial pneumonia, including ventilator-associated
pneumonia (VAP).

The cash-for-stock transaction is valued at approximately
$245 million and is expected to close in the second quarter.
Upon closing, Johnson & Johnson expects to incur a one-time
after-tax charge of approximately $0.08 per share, as
substantially all of the purchase price will be expensed as
in-process research and development.

Exhibit No.       Description of Exhibit

99.15     Press Release dated April 19, 2005


Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly

                                   JOHNSON & JOHNSON

Date: April 21, 2005       By: /s/ Stephen J. Cosgrove
                               Stephen J. Cosgrove
                               Chief Accounting Officer